logo
Plus   Neg
Share
Email

JinkoSolar Says Disagree With Düsseldorf Court Decision In Patent Litigation Brought By Hanwha

JinkoSolar Holding Co. Ltd. (JKS) responded to the Regional Court of Düsseldorf's recent determination concluding that third-party cell technology contained in certain JinkoSolar modules, no longer in production, infringes a patent held by Hanwha Q CELLS.

"We respectfully disagree with the recent decision of the Düsseldorf court, which did not take any independent expert evidence and based its decision on one sided allegations," said Kangping Chen, CEO of JinkoSolar.

JinkoSolar believes the Düsseldorf court came to an erroneous conclusion and will appeal the decision. JinkoSolar is also challenging the Hanwha patent's validity at the European Patent Office.

JinkoSolar continues to believe that Hanwha's claims are without merit and were brought solely to slow down its business momentum.

Importantly, the scope and impact of the Düsseldorf court's decision is limited to Germany. Additionally, the decision relates to third-party cells included in older versions of JinkoSolar-branded modules which are no longer in production. As such, the decision has no impact on current JinkoSolar customers, and JinkoSolar may continue to import and sell modules that use its own cell technology to customers in Germany.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test. AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory...
Follow RTT